查詢結果分析
來源資料
頁籤選單縮合
| 題 名 | 新型減重藥物介紹=New Anti-Obesity Agents |
|---|---|
| 作 者 | 陳思綺; | 書刊名 | 內科學誌 |
| 卷 期 | 36:3 2025.06[民114.06] |
| 頁 次 | 頁161-165 |
| 分類號 | 411.94 |
| 關鍵詞 | 肥胖; 減重; 藥物治療; 腸泌素; Obesity; Weight loss; Medical treatment; Incretin; |
| 語 文 | 中文(Chinese) |
| DOI | 10.6314/JIMT.202506_36(3).01 |
| 中文摘要 | 治療肥胖為目前全球重要的公共衛生議題。當飲食控制、運動及行為治療無法達到減重目標時可考慮藥物輔助。現行指引建議身體質量指數BMI≥30kg/m2或BMI≥27 kg/m2且有共病症者使用藥物治療。除了羅氏鮮(Xenical®)外,台灣近年核可多種減重藥物使用包括康纖芙(Contrave®)、善纖達(Saxenda®)、週纖達(Wegovy®)以及即將被核准的猛健樂(Mounjaro®)。這些藥物通過不同機制抑制食慾或增加飽足感,幫助減重並改善代謝指標,在臨床研究中也證實其減重療效。然使用前需熟知正確用法、副作用及禁忌症等以達到安全療效。本文將介紹新型減重藥物的減重實證效應及使用注意事項。 |
| 英文摘要 | Obesity treatment is currently a significant global public health concern. Anti-obesity medications are recommended for adults with obesity or overweight and weight-related complications who do not adequately respond to lifestyle modifications. In Taiwan, in addition to Orlistat®, several weight loss medications have been approved in recent years, including Contrave Extended-Release tablets®, Saxenda®, Wegovy®, and the soon-to-be-approved Mounjaro®. These medications work through different mechanisms to suppress appetite or increase satiety, aiding in weight loss and improving metabolic indicators. Their weight loss efficacy has been confirmed in clinical studies. However, it is crucial to understand the correct usage, side effects, and contraindications before using these medications to ensure their safety and effectiveness. This article will present the evidence for the weight loss effects and usage precautions of these new weight loss medications. |
本系統中英文摘要資訊取自各篇刊載內容。